

IN THE SPECIFICATION

Please insert the attached sequence listing into the specification after the Abstract

Please amend the paragraph beginning on page 31, line 1 as follows:

6 NC/Nga mice were divided into two group: an MB-ODN4/5#31-treated group and an untreated group. The ointment (0.2 mg/head) including the resultant O-type MB-ODN4/5#31 was applied onto a lesion site of the atopic dermatitis in the back of the treated group of the mice every five days during 2 weeks (total 4 times). Petrolatum devoid of the CpG ODN of the present invention was applied to the untreated group of the mice in the same manner as described above.